KPTI - Karyopharm Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
18.93
-0.26 (-1.35%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.19
Open19.21
Bid18.25 x 4600
Ask19.89 x 2200
Day's Range18.90 - 19.35
52 Week Range8.00 - 20.39
Volume357,260
Avg. Volume874,830
Market Cap1.145B
Beta4.52
PE Ratio (TTM)N/A
EPS (TTM)-2.88
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.60
Trade prices are not sourced from all markets
  • Karyopharm Initiates NDA Submission Process for Selinexor
    Zacks2 days ago

    Karyopharm Initiates NDA Submission Process for Selinexor

    Karyopharm Therapeutics (KPTI) initiates rolling submission of a New Drug Application to the FDA with a request for accelerated approval for selinexor.

  • GlobeNewswire3 days ago

    Karyopharm Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma

    --Company Plans to Complete Submission During the Second Half of 2018--. NEWTON, Mass., July 18, 2018-- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that the Company ...

  • ACCESSWIRE10 days ago

    Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on MNK sign up now at www.wallstequities.com/registration. WallStEquities.com takes a look at the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the generic drugs market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others.Under monitoring this morning are four equities: Galectin Therapeutics Inc. (NASDAQ: GALT), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Lannett Co. Inc. (NYSE: LCI), and Mallinckrodt PLC (NYSE: MNK).

  • GlobeNewswire19 days ago

    Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 146,500 shares of Karyopharm’s common stock to twenty newly-hired employees, with a grant date of June 29, 2018.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $16.99 per share, the closing price of Karyopharm’s common stock on June 29, 2018.

  • GlobeNewswire26 days ago

    Karyopharm Appoints Anand Varadan as Chief Commercial Officer and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Anand Varadan as Executive Vice President, Chief Commercial Officer. In this role, Mr. Varadan will lead Karyopharm’s commercial strategy and operations, including for the launch of selinexor, the Company’s lead, novel, oral SINE compound.

  • GlobeNewswirelast month

    Karyopharm Presents Updated Selinexor Phase 1b/2 STOMP Myeloma Data from Multiple Combinations at the European Hematology Association 2018 Annual Meeting

    --SVd Once Weekly Demonstrates 17.8- month PFS and 83% ORR in the BOSTON Multiple Myeloma Population; 63% ORR in the Overall Study Population--. --SDd Once Weekly Shows 82% ORR in Patients with Heavily ...

  • CNBClast month

    Cramer's lightning round: I was wrong to sell Magellan Midstream Partners

    Jim Cramer admits he was wrong about selling a pipeline play for his charitable trust in the lightning round.

  • GlobeNewswire2 months ago

    Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 77,000 shares of Karyopharm’s common stock to seven newly-hired employees, with a grant date of May 31, 2018.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $18.58 per share, the closing price of Karyopharm’s common stock on May 31, 2018.

  • ACCESSWIRE2 months ago

    Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / June 1, 2018 / If you want a free Stock Review on MNK sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com scans Galectin Therapeutics Inc. (NASDAQ: GALT), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Lannett Co. Inc. (NYSE: LCI), and Mallinckrodt PLC (NYSE: MNK).

  • GlobeNewswire2 months ago

    Karyopharm to Present Selinexor Phase 2/3 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting

    Treatment with Selinexor Prolongs Progression-Free Survival Compared to Placebo in Patients with Liposarcoma. Additional Selinexor Data Posters from Investigator-Sponsored Trials Show Early Signals of ...

  • GlobeNewswire2 months ago

    Karyopharm to Participate in Upcoming Investor Conferences

    NEWTON, Mass., May 31, 2018-- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in the following ...

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind PDC Energy, Black Stone Minerals, BJ's Restaurants, Karyopharm Therapeutics, SBA Communications, and BLACKLINE INC — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, May 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PDC ...

  • ACCESSWIRE2 months ago

    Blog Exposure - Karyopharm Inked Deal with Antengene for Development and Commercialization of Selinexor, Eltanexor, Verdinexor, and KPT-9274 in Asia

    LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Karyopharm Therapeutics Inc. (NASDAQ: KPTI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KPTI as the Company's latest news hit the wire. On May 24, 2018, the Company announced that it has signed an exclusive license agreement with Antengene Corp. for the development and commercialization of four of Karyopharm's novel, oral drug candidates, including selinexor, eltanexor, verdinexor, and KPT-9274. Active-Investors.com is currently working on the research report for PetIQ, Inc. (NASDAQ: PETQ), which also belongs to the Healthcare sector as the Company Karyopharm Therapeutics.

  • GlobeNewswire2 months ago

    Karyopharm and Antengene Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia

    Karyopharm Therapeutics Inc. (KPTI) (Karyopharm) and Antengene Corporation (Antengene), today announced their entry into an exclusive license agreement for the development and commercialization of four of Karyopharm’s novel, oral drug candidates, including selinexor, Karyopharm’s lead SINE compound, eltanexor, Karyopharm’s second-generation SINE compound, verdinexor, Karyopharm’s lead compound in development for viral and other non-oncology indications, and KPT-9274, Karyopharm’s dual inhibitor of PAK4 and NAMPT. The agreement includes the development and commercialization of selinexor and eltanexor for the diagnosis, treatment and/or prevention of all human oncology indications in China and Macau.  The agreement also includes the development and commercialization of KPT-9274 in all human oncology indications and verdinexor in human non-oncology indications in mainland China, Macau, Taiwan, Hong Kong, South Korea, and the ASEAN countries.

  • GlobeNewswire2 months ago

    Karyopharm to Present Selinexor Phase 1b/2 STOMP Data at the European Hematology Association 2018 Annual Meeting

    NEWTON, Mass., May 17, 2018-- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that three posters highlighting clinical data from the ongoing Phase 1 b/2 STOMP study ...

  • GlobeNewswire2 months ago

    Karyopharm to Present Selinexor Phase 2 SEAL Data at the American Society of Clinical Oncology 2018 Annual Meeting

    NEWTON, Mass., May 16, 2018-- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that four posters will be presented at the upcoming American Society of Clinical Oncology ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of KPTI earnings conference call or presentation 10-May-18 12:30pm GMT

    Q1 2018 Karyopharm Therapeutics Inc Earnings Call

  • Associated Press2 months ago

    Karyopharm Therapeutics: 1Q Earnings Snapshot

    The Newton, Massachusetts-based company said it had a loss of 78 cents per share. The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    Karyopharm Reports First Quarter 2018 Financial Results and Highlights Recent Progress

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2018 and provided an overview of recent accomplishments and clinical development plans for selinexor, its lead, novel, oral SINE compound, eltanexor, its second-generation oral SINE compound, and KPT-9274 its novel, oral, dual inhibitor of PAK4 and NAMPT.

  • GlobeNewswire2 months ago

    Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced the closing of its previously announced registered underwritten public offering and the exercise in full of the underwriters’ option to purchase additional shares.  10,525,424 shares of the Company’s common stock at a price to the public of $14.75 per share were issued and sold in the offering, which includes 1,372,881 shares issued upon the exercise of the underwriters’ option to purchase additional shares.  The gross proceeds to Karyopharm from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $155 million. J.P. Morgan, Jefferies and Leerink Partners acted as joint book-running managers for the offering.  Canaccord Genuity, JMP Securities, H.C. Wainwright & Co. and Baird acted as co-managers for the offering.

  • GlobeNewswire3 months ago

    Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 103,500 shares of Karyopharm’s common stock to 16 newly-hired employees, with a grant date of April 30, 2018.  The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with NASDAQ Listing Rule 5635(c)(4). Each of the stock options has an exercise price of $13.08 per share, the closing price of Karyopharm’s common stock on April 30, 2018.

  • GlobeNewswire3 months ago

    Karyopharm to Report First Quarter 2018 Financial Results on May 10, 2018

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2018 financial results on Thursday, May 10, 2018. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, May 10, 2018 to discuss the financial results and recent business developments. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations.

  • GlobeNewswire3 months ago

    Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced the pricing of its previously announced registered underwritten public offering of 9,152,543 shares of its common stock at a price to the public of $14.75 per share.  The gross proceeds to Karyopharm from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be $135.0 million.  The offering is expected to close on or about May 7, 2018, subject to customary closing conditions. In addition, Karyopharm has granted the underwriters a 30-day option to purchase up to 1,372,881 additional shares of its common stock. J.P. Morgan, Jefferies and Leerink Partners are acting as joint book-running managers for the offering.  Canaccord Genuity, JMP Securities, H.C. Wainwright & Co. and Baird are acting as co-managers for the offering.

  • GlobeNewswire3 months ago

    Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock

    Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, today announced the commencement of a registered underwritten public offering of $125 million in shares of its common stock. In addition, Karyopharm also intends to grant the underwriters a 30-day option to purchase up to $18.75 million in shares of its common stock. J.P. Morgan, Jefferies and Leerink Partners are acting as joint book-running managers for the offering.  Canaccord Genuity, JMP Securities, H.C. Wainwright & Co. and Baird are acting as co-managers for the offering.

  • Why Karyopharm Therapeutics Inc. Shares Are Soaring 15% Today
    Motley Fool3 months ago

    Why Karyopharm Therapeutics Inc. Shares Are Soaring 15% Today

    This clinical-stage company reported significant news yesterday.